PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 23 filers reported holding PROQR THRAPEUTICS N V in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $952,000 | -4.7% | 309,700 | 0.0% | 0.00% | – |
| Q4 2017 | $999,000 | -33.5% | 309,700 | 0.0% | 0.00% | -100.0% |
| Q3 2017 | $1,502,000 | -6.7% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $1,610,000 | +3.9% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $1,549,000 | +2.0% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $1,518,000 | -26.5% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $2,066,000 | +37.8% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $1,499,000 | -0.8% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $1,511,000 | -43.8% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $2,688,000 | -40.4% | 309,700 | 0.0% | 0.00% | -50.0% |
| Q3 2015 | $4,512,000 | -1.6% | 309,700 | +12.6% | 0.00% | 0.0% |
| Q2 2015 | $4,584,000 | -23.8% | 275,000 | 0.0% | 0.00% | -33.3% |
| Q1 2015 | $6,017,000 | +1.0% | 275,000 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $5,959,000 | +26.1% | 275,000 | 0.0% | 0.00% | +50.0% |
| Q3 2014 | $4,727,000 | – | 275,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 748,861 | $6,815,000 | 2.37% |
| Opus Point Partners Management, LLC | 138,461 | $1,260,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,722,950 | $33,879,000 | 1.81% |
| Kerrisdale Advisers, LLC | 465,580 | $4,237,000 | 1.52% |
| DAFNA Capital Management LLC | 261,521 | $2,380,000 | 0.90% |
| SPHERA FUNDS MANAGEMENT LTD. | 470,000 | $4,277,000 | 0.58% |
| Artal Group S.A. | 1,300,000 | $11,830,000 | 0.48% |
| Orbimed Advisors | 1,382,502 | $12,581,000 | 0.20% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 56,000 | $511,000 | 0.19% |
| ALTRINSIC GLOBAL ADVISORS LLC | 201,360 | $1,832,000 | 0.08% |